BSI-730

N/A

Report date: 2024/03/22 17:12:08

Base Information

Drug NameBSI-730

Drug Alias NameBSI-730

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-HER2Anti-Programmed death-ligand 1

TargetsReceptor protein-tyrosine kinase erbB-2Programmed death-ligand 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesBiosion Inc

China Registration ClassN/A

Develop Information

Active CompaniesBiosion Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A